REFERENCES
- Korte JM, Kaila T., Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eye drops, Graefe's Arch Clin Exp Ophthalmol 2002; 240: 430–435.
- Dunn FG, Frohlich ED. Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a non‐selective beta‐adrenoreceptor blocking agent Pharmacotherapy 1981; 1: 188–200.
- Rouland JF, Morel‐mandaino P., Elana PP, Polzer H., Sunderraj P.. Timolol 0.1% gel (Nyogel 0.1%) once daily versus conventional timolol 0.5% solution twice daily: A comparison of efficacy and safety. Ophthalmologica 2002; 216: 449–454.
- Nino J., Tahvanainen K., Uusitalo H., Turjanmaa V., Hutri‐kahonen N., Kaila T., Ropo A., Kuusela T., Kahonen M.. Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Clin Physiol Func Imaging 2002; 22: 271–278.
- Ardjomand N. et al. Efficacy of 0.1% timolol hydrogel (Nyolol 0.1% Gel) in patients with primary open angle glaucoma and ocular hypertension. Spektrum Augenheilk 2000; 14: 203–208.
- Australian Approved Nyogel Product Information.
- Vannewkirk MR, Weih L., Mccarty CA, Taylor HR. Cause‐specific prevalence of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project. Ophthalmology 2001; 108: 960–967.
- Craven ER. Twelve‐month randomised comparison of fixed combination brimonidine 0.2%/timolol 0.5% with each component as monotherapy. American Academy of Ophthalmology Annual Meeting Poster P0058. Oct 25 2004 Additional source: www.medisave.caDrugMoreInfo2546.aspx.
- Barequet IS, Denton P., Osterhout GJ, Tulli S., O'brien TP. Treatment of experimental bacterial keratitis with topical trovofloxacin. Arch Ophthalmol 2004; 122: 65–69.